LAFAYETTE, L. (KLFY) — Dominant pitching outings from Andrew Herrmann and Cody Brasch, along with a combined 22 hits helped Louisiana claim a doubleheader sweep of Georgia State, winning the opener, 14-1, before posting a 5-1 victory in the nightcap on Saturday at M.L. “Tigue” Moore Field at Russo Park.

Colt Brown and Donovan LaSalle belted home runs in the opener to help lead a 10-hit attack while Noah Lewis went 3-for-5 with two RBI in the nightcap to lead Louisiana (29-18, 11-12 SBC) to its fourth straight win, its seventh victory in its last eight games and its first doubleheader Sweep in SBC play since facing South Alabama in 2023.

GAME 1 – LOUISIANA 14, GEORGIA STATE 1 (7 innings)
Herrmann (6-2) scattered five hits and fanned six batters in recording his fourth complete game
of the season and moving into a tie for the national lead with Jaden Wywoda of Holy Cross. The
southpaw kept GSU off the board until the seventh when Wesley Bass hit a solo homer to help
the Panthers avoid a shutout.

Louisiana took a 3-0 lead in the second inning, beginning with Brown’s fourth home run of the
the season off GSU starter Brian Crooms (3-4) – a 411-foot blast to center. The Ragin’ Cajuns
added two more runs in the frame when Drew Markle lifted a sacrifice fly to drive in Blaze
Rodriguez before Steven Spalitta slid in under the tag of Panther’s catcher Lucas Grantham on a
double steal.

The Ragin’ Cajuns scored seven runs in the third as Brown drove in Lee Amedee with a bloop
single to left for a 4-0 lead. Spalitta added an RBI single to plate Rigoberto Hernandez and
Brown scored on a balk before Markle hit an RBI double into the left-center field gap.
Amedee drew a bases-loaded walk for an 8-0 lead before a wild throw on a pickoff led to runs
by Mark Collins and Lewis.

LaSalle increased Louisiana’s lead to 13-0 in the fourth after plastering a 0-and-1 pitch for his
eighth homer of the season – a three-run, 424-foot drive to left.

The Cajuns added their final run in the fifth as Lewis scored on a fielding error.
Crooms allowed four runs on a pair of hits in 2.0 innings of work. Bass went 2-for-3 for the

Panthers with Austin Killingworth and Cole Griffith each adding doubles.

GAME 2 – LOUISIANA 5, GEORGIA STATE 1
Brasch (4-2) notched his second straight quality start after allowing one hit, retiring 15 straight
batters and striking out three over 6.2 innings of work. Tyler Papenbrock pitched the final 2.1
innings to earn his first save of the season.

Louisiana broke open a scoreless game in the third as Markle led off with a single and scored on
Lewis’ RBI double to center. Amedee followed with an RBI single to right field off GSU starter
Michael Caruso (5-6) to give the Cajuns a 2-0 lead.

With a 2-0 lead in the seventh, Papenbrock came in to relieve Brasch after Griffith reached on a
two-out, two-base error and got Bass to ground out to second to preserve the lead

The Cajuns increased their lead to 3-0 in the bottom half of the frame as Brown drew a bases loaded walk off GSU reliever Nicholas Holbrook and scored twice in the eighth after the
Panthers cut the deficit to 3-1 in the eighth on Sam Silas drove in Killingsworth on an RBI
groundout.

LaSalle reached on a fielder’s choice and Markle was hit by a pitch before Collins singled
through the left side to drive in LaSalle for a 4-1 lead. After a GSU error moved both runners
into scoring position, Lewis chopped an RBI single up the third-base line to plate Markle.

Louisiana recorded 12 hits off four GSU pitchers with Collins, Rodriguez and Spalitta recording
two hit each. The combination of Brasch and Papenbrock produced 16 groundball outs and
allowed four base runners on the day.

Latest news

The Louisiana Lottery offers several draw games for those aiming to win big.

Here’s a look at May 2, 2026, results for each game:

Winning Powerball numbers from May 2 drawing

25-37-42-52-65, Powerball: 14, Power Play: 3

Check Powerball payouts and previous drawings here.

Winning Pick 3 numbers from May 2 drawing

9-3-8

Check Pick 3 payouts and previous drawings here.

Winning Pick 4 numbers from May 2 drawing

6-2-0-0

Check Pick 4 payouts and previous drawings here.

Winning Pick 5 numbers from May 2 drawing

6-2-4-2-6

Check Pick 5 payouts and previous drawings here.

Winning Easy 5 numbers from May 2 drawing

01-03-08-18-34

Check Easy 5 payouts and previous drawings here.

Winning Lotto numbers from May 2 drawing

17-19-21-32-36-41

Check Lotto payouts and previous drawings here.

Feeling lucky? Explore the latest lottery news & results

Are you a winner? Here’s how to claim your lottery prize

All Louisiana Lottery retailers will redeem prizes up to $600. For prizes over $600, winners can submit winning tickets through the mail or in person at Louisiana Lottery offices. Prizes of over $5,000 must be claimed at Lottery office.

By mail, follow these instructions:

1. Sign and complete the information on the back of your winning ticket, ensuring all barcodes are clearly visible (remove all scratch-off material from scratch-off tickets).
2. Photocopy the front and back of the ticket (except for Powerball and Mega Millions tickets, as photocopies are not accepted for these games).
3. Complete the Louisiana Lottery Prize Claim Form, including your telephone number and mailing address for prize check processing.
4. Photocopy your valid driver’s license or current picture identification.

Mail all of the above in a single envelope to:

Louisiana Lottery Headquarters

555 Laurel Street

Baton Rouge, LA 70801

To submit in person, visit Louisiana Lottery headquarters:

555 Laurel Street, Baton Rouge, LA 70801, (225) 297-2000.

Hours: 8 a.m. to 4:30 p.m., Monday through Friday. This office can cash prizes of any amount.

Check previous winning numbers and payouts at Louisiana Lottery.

On Saturday, two companies that manufacture mifepristone came to the court in Danco Laboratories v. Louisiana, asking the justices to pause a ruling by the U.S. Court of Appeals for the 5th Circuit in a lawsuit by Louisiana that reinstated the requirement that the drug, which is used in about 60% of abortions nationwide, be dispensed only in person. Danco and GenBioPro told the justices that the 5th Circuit’s order was “unprecedented” and “injects immediate confusion and upheaval into highly time-sensitive medical decisions.”

Nearly two years ago, the Supreme Court ruled that doctors and medical groups opposed to abortion did not have a legal right to sue, known as standing, to challenge the Food and Drug Administration’s expansion of access to mifepristone.

The 2024 case, FDA v. Alliance for Hippocratic Medicine, was filed in federal court in Texas by several individual doctors who are opposed to abortion on religious or moral grounds, as well as medical groups whose members are opposed to abortion. The plaintiffs asked U.S. District Judge Matthew Kacsmaryk to rescind both the FDA’s initial approval of the drug in 2000 and its 2016 and 2021 expansions of access to the drug, arguing that mifepristone is unsafe and that the process that the FDA used to approve the drug was flawed.

The FDA, as well as several leading medical groups, countered that, based on extensive evidence, mifepristone is safe and effective. Kacsmaryk, however, suspended the FDA’s approval of the drug and the agency’s later changes, made in 2016 and 2021, to the conditions on the use of the drug – which included allowing the drug to be used through the 10th week of pregnancy, allowing health-care providers who are not physicians to prescribe the drug, and permitting it to be prescribed without an in-person visit.

The FDA and Danco, which manufactures mifepristone, appealed to the 5th Circuit. The court upheld the part of Kacsmaryk’s ruling that rolled back the agency’s 2016 and 2021 changes that had expanded access to mifepristone.

In April 2023, the Supreme Court temporarily put the 5th Circuit’s ruling on hold, ensuring continued access to the drug. In June 2024, it reversed the lower court’s ruling and sent the case back to the lower courts.

In his opinion for the court, Justice Brett Kavanaugh acknowledged what he characterized as the challengers’ “sincere legal, moral, ideological, and policy objections” to elective abortion “by others” and to FDA’s 2016 and 2021 changes to the conditions on the use of the drug. But the challengers could not contest those changes, he said, because they had not shown that they would be harmed by the FDA’s mifepristone policies; under the Constitution, these kinds of objections are not enough to bring a case in federal court.

In October 2025, Louisiana filed its own lawsuit in federal court to seek the reinstatement of the in-person dispensing requirement. It emphasized that it had standing to sue because it had “incontrovertible evidence that … doctors and others are (as the Biden administration intended) sending streams of mifepristone by mail into Louisiana for the express purpose of causing thousands of abortions in Louisiana every year. That conduct directly violates Louisiana’s abortion laws, which – subject to very narrow exceptions (such as to save the life of the mother) – bar virtually all abortions, and prevents Louisiana from protecting the lives of unborn babies despite the promise of Dobbs” v. Jackson Women’s Health Organization, the Supreme Court’s 2022 decision holding that the Constitution does not confer a right to an abortion. “That conduct has directly generated medical emergencies that harm Louisiana women,” the state wrote, “and emergency room visits that harm the state.”

Rosalie Markezich, an individual plaintiff who joined the state’s lawsuit, said that in 2023 she was coerced into taking abortion drugs “that her boyfriend obtained via the U.S. Postal Service from a doctor in California.” If the in-person dispensing requirement had been in effect, she said, she “would have received the protection of a private in-person medical appointment,” during which she would “have been able to tell a doctor that she did not want an abortion.”

After a federal judge put the case on hold while the FDA conducts its own review of mifepristone’s safety, Louisiana went to the 5th Circuit, asking that court to re-impose the requirement while litigation continues. The court of appeals ruled that Louisiana has a right to sue because, by allowing mifepristone to be prescribed by telehealth and sent by mail, the “FDA ‘opened the door for mifepristone to be remotely prescribed to Louisiana women,’” even though Louisiana generally bars abortion.

In their emergency application, the drug companies tell the justices that, like the doctors and medical groups in 2024, “Louisiana is not required to ‘prescribe or use mifepristone’ or to ‘do anything or to refrain from doing anything’ as a result of FDA’s actions.” The companies argue that the 5th Circuit should have applied the same analysis that the Supreme Court used in holding that the doctors and medical groups did not have standing in 2024. They stress that the Supreme Court “has already held that claims of downstream financial harm by doctors who provide follow-up care for treating complications after a medication abortion is too attenuated” to provide standing to sue. Here, they say, “Louisiana’s theory—that it can base standing on having to pay those doctors if someone who received FDA-approved mifepristone through the mail seeks follow-up care to treat a complication—is a more attenuated version of the” theories that the court specifically rejected two years ago. And Louisiana’s claim that it is injured because of the disconnect between federal law and its own state law is not the kind of injury that courts can review, they said.

The drug companies also ask the court to issue a short-term order, known as an administrative stay, that would put the 5th Circuit’s ruling on hold while the justices consider their request.

The drug companies’ request goes initially to Justice Samuel Alito, who handles emergency requests from the 5th Circuit. Alito is likely to ask Louisiana to respond before acting on the companies’ request.